BACKGROUND: Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality
after lung transplantation despite ganciclovir prophylaxis. The emergence of ganciclovir …

BACKGROUND: Since ganciclovir-resistant cytomegalovirus (CMV) disease was initially
described in a patient with acquired immunodeficiency syndrome (AIDS) in 1986, the …

Background. Cytomegalovirus (CMV) resistance to ganciclovir has become increasingly
common in acquired immu; nodeficiency syndrome patients but has only rarely been …

Background Cytomegalovirus (CMV) infection results in significant morbidity and mortality in
lung transplant recipients. Ganciclovir (GCV) has dramatically reduced complications …

Ganciclovir-resistant cytomegalovirus (CMV) infections are reported infrequently among
lung transplant recipients receiving extended valganciclovir prophylaxis. We performed a …

Clinical consequences of ganciclovir resistant cytomegalovirus (CMV) infections were
studied during 2 large prophylactic trials consisting of 100 days of valganciclovir or …

Cytomegalovirus (CMV) is a common opportunistic infection in lung transplant recipients.
Despite the use of early post‐operative intravenous ganciclovir, most high‐risk patients …

Cytomegalovirus (CMV) infection remains a serious problem in lung transplant recipients.
Development of potent oral antiviral agents, molecular techniques for the detection of …

In the era of more aggressive immunosuppressive regimens and antiviral prophylaxis,
ganciclovir-resistant cytomegalovirus (CMV) has been recognized as an important clinical …

BACKGROUND: Valganciclovir prophylaxis is advocated for lung transplant recipients, but
its efficacy is unknown. METHODS: Retrospective review was done of 109 donor …